ALA AU0000182784

Rapporto

Tempo differito Australian Stock Exchange - 07:51 28/06/2022
0.0240	AUD		+9.09%

01:04	Arovella Therapeutics Limited fornisce un aggiornamento sul Sumatriptan	CI
22/06	Il partner di Arovella Therapeutics, STADA, inizia il lancio commerciale del farmaco contro l'insonnia in Australia.	MT
22/06	Arovella Therapeutics Limited annuncia il lancio di ZolpiMist in Australia	CI

Notizie

Altre lingue

Pubblicazioni ufficiali

Notizie del settore

Notizie in altre lingue su AROVELLA THERAPEUTICS LIMITED

01:04	Arovella Therapeutics Limited Provides Sumatriptan Update
22/06	Arovella Therapeutics Partner STADA Begins Commercial Launch of Insomnia Drug in Austra..
22/06	Arovella Therapeutics Limited Announces ZolpiMist Launch Australia
09/06	Arovella Therapeutics Adopts WEF Framework for ESG Reporting
08/06	AROVELLA THERAPEUTICS: Adopts WEF Framework For ESG Reporting
07/06	Arovella Therapeutics Ltd Announces Executive Changes
20/04	Arovella Therapeutics Limited Signs Services Agreement with Qimr Berghofer Medical Rese..
05/04	Arovella Therapeutics Ltd Announces That the US Patent and Trademark Office Has Accepte..
17/03	AROVELLA THERAPEUTICS: Proposed issue of securities - ALA
16/03	AROVELLA THERAPEUTICS: Application for quotation of securities - ALA
28/02	AROVELLA THERAPEUTICS: Update - Proposed issue of securities - ALA
28/02	Arovella Therapeutics Limited Reports Earnings Results for the Half Year Ended December..
01/02	Arovella Therapeutics Limited announced that it has received AUD 4.568748 million in fu..
24/01	Arovella Therapeutics Limited announced that it expects to receive AUD 4.568748 million..
2021	Arovella Therapeutics Secures Licensing Rights for Anti-Cancer Therapy
2021	Arovella Therapeutics Ltd Announces Appointment of Elizabeth Stoner as Non-Executive Di..
2021	Arovella Therapeutics Ltd Announces Executive Changes
2021	SUDA PHARMACEUTICALS: Changes Name to Arovella Therapeutics; Shares Jump 4%
2021	SUDA Pharmaceuticals Ltd Announces Chile Ministry of Health Approval Granted to Teva Ph..
2021	SUDA Pharmaceuticals Ltd Appoints John Maher to Scientific Advisory Board
2021	Suda Pharmaceuticals Ltd Reports Earnings Results for the Full Year Ended June 30, 2021
2021	SUDA Pharmaceuticals Ltd Appoints Reuben Benjamin to Scientific Advisory Board
2021	Suda Pharmaceuticals Ltd Signs Licence and Distribution Agreement with Stada Pharmaceut..
2021	Suda Pharmaceuticals Ltd Provides ZolpiMist Update
2021	Suda Pharmaceuticals Ltd Has Enters into Collaborative Research Agreement with Imperial..
2021	Suda Pharmaceuticals Ltd Announces Appointment of Dr. Debora Barton as Non-Executive Di..
2021	SUDA PHARMACEUTICALS: Raises Nearly $3 Million to Develop Cell Therapy Platform; Shares S..
2021	SUDA PHARMACEUTICALS: Acquires License for Cancer Cell Therapy Platform from UK Instituti..
2021	Suda Licenses A Novel iNKT Cell Therapy Platform
2021	Suda Pharmaceuticals Ltd Appoints Professor Gunnar Birgegård as Scientific Advisory Boa..
2021	Suda Pharmaceuticals Ltd Appoints of Dr. Anil K. Sood to its Scientific Advisory Board
2021	Suda Pharmaceuticals Ltd Reports Earnings Results for the Half Year Ended December 31, ..
2021	SUDA PHARMACEUTICALS: Down 7% as Mitsubishi Tanabe Pharma Singapore Backs Out of ZolpiMis..
2021	SUDA Has Agrees to Terminate the Agreement with Mitsubishi Tanabe Pharma Singapore Pte ..
2021	Tony Macintyre and Michael Baker to Assume the Role of Chief Technical Officer of Suda ..
2020	Suda Pharmaceuticals Ltd Announces Ordesa Feasibility Study Update
2020	SUDA PHARMACEUTICALS: Gets R&D Tax Refund
2020	Suda Pharmaceuticals Ltd. Receives the Final Report for a Canine Pharmacokinetic Study
2020	Suda Pharmaceuticals Ltd Reports Earnings Results for the Full Year Ended June 30, 2020
2020	Suda Pharmaceuticals Ltd Announces Executive Changes
2020	AYTU BIOSCIENCE: Announces Regulatory Approval of ZolpiMist by Australian Therapeutic Goo..
2020	Suda Pharmaceuticals Ltd Appoints Phillip Hains as Joint Company Secretary
2020	Suda Pharmaceuticals Ltd Announces Change of Registered Office
2020	Suda Pharmaceuticals Ltd Appoints Michael Baker as A Director
2020	Suda Pharmaceuticals Ltd Provides Anagrelide Project Update
2020	Suda Pharmaceuticals Ltd Receives Grant from Japanese Patent Office for the Application..
2020	Suda Pharmaceuticals Ltd Provides Update on ZolpiMist Oral Spray
2020	Aytu BioScience Announces Exclusive ZolpiMist License to Commercialize Aytu's Oral Spra..
2020	Mitsubishi Tanabe Pharma Korea Co Ltd Enters into Licensing Agreement with Suda Pharmac..
2020	Suda Pharmaceuticals Ltd Reports Earnings Results for the Half Year Ended December 31, ..
2019	Laboratorios Ordesa, S.L Pharmaceuticals Ltd Signs Co-Development Deal with Laboratorio..
2019	SUDA Pharmaceuticals Limited Announces Management Changes
2019	Suda Pharmaceuticals Ltd Announces Management Changes
2019	SUDA Pharmaceuticals Limited Announces Finalised the Product Development, Licence and S..
2019	Suda Pharmaceuticals Ltd Announces Executive Changes
2019	Suda Pharmaceuticals Ltd Reports Earnings Results for the Full Year Ended June 30, 2019
2019	Suda Pharmaceuticals Ltd Announces Richard Franklin as Project Director
2019	SUDA Pharmaceuticals Ltd Announces Zolpimist Clinical Study Results Demonstrating Lingu..
2019	Uropean Patent Office Informs Suda That It Intends to Grant Anagrelide Patent
2019	Suda Pharmaceuticals Ltd Provides an Update to the ArTiMist® Regulatory
2019	Suda Pharmaceuticals Ltd Signs Binding Term Sheet with Cann Pharmaceutical Australia
2019	Suda Pharmaceuticals Ltd Enters into Agreements with Two International Specialty Consul..
2019	Suda Pharmaceuticals Ltd Announces Cessation of Joseph Daniel Ohayon as Director
2019	Suda Pharmaceuticals Ltd Announces Management Changes
2019	SUDA Pharmaceuticals Ltd Receives Preliminary Notice of Denial for Marketing Approval o..
2019	SUDA Submits Marketing Authorization Application for Zolpimist
2019	SUDA Appoints David Simmonds to the Board as a Non-Executive Director
2019	Suda Pharmaceuticals Ltd Provides Update on its Development of Anagrelide
2019	Suda Pharmaceuticals Ltd Reports Earnings Results for the Half Year Ended December 31, ..
2019	Suda Pharmaceuticals Ltd Provides Update on its Development of Anagrelide
2018	Suda Signs Licence Agreement with Mitsubishi Tanabe for ZolpiMist
2018	Suda Pharmaceuticals Ltd Updates ZolpiMist Insomnia Product Development Market
2018	Strides Pharma Global Enters into Licensing Agreement with SUDA Pharma
2018	Suda Pharmaceuticals Ltd Appoints Andrew Curtis as Vice President, Effect from 15 Octob..
2018	Suda Pharmaceuticals Ltd. Reports Audited Consolidated and Parent Earnings Results for ..

1 2 Succ.

Prossimo evento su AROVELLA THERAPEUTICS LIMITED

31/08/22

Esercizio 2022 Pubblicazione dei risultati (proiezione)

Calendario della società

Prossimi eventi del settore

22/07/22	LONZA GROUP AG: Primo semestre 2022 Pubblicazione dei risultati
26/07/22	IQVIA HOLDINGS INC.: Primo semestre 2022 Pubblicazione dei risultati (proiezione)
28/07/22	SEAGEN INC.: Primo semestre 2022 Pubblicazione dei risultati (proiezione)
03/08/22	MODERNA, INC.: Primo semestre 2022 Pubblicazione dei risultati (proiezione)

Più eventi

Settore

Sanità
	Biotecnologia/Farmaceutici
		Biotecnologia e ricerca medica
			Biotecnologia
				Biotecnologia e ricerca medica - Altri